BCAX -
Bicara Therapeutics Inc. Common Stock
| Day |
1m |
10m |
60m |
PreMarket |
Market |
AfterHours |
Gap |
| 16.6 1.48 (8.92%) |
0.0 (0.03%) |
0.01 (0.05%) |
0.04 (0.22%) |
0.0 (0.0%) |
1.95 (12.09%) |
--- |
0.0 (0.0%) |
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.
Earnings & Ratios
- Basic EPS:
- -0.5
- Diluted EPS:
- -0.5
- Basic P/E:
- -36.16
- Diluted P/E:
- -36.16
- RSI(14) 1m:
- 71.87
- VWAP:
- 18.08
- RVol:
Events
| Period |
Kind |
Movement |
Occurred At |
Related News
Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12
Dec 15, 2025 13:00
Bicara Therapeutics’ Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026
Dec 06, 2025 13:00
Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology
Oct 27, 2025 12:30
Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025
Jun 01, 2025 17:12
Bicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 ASCO Annual Meeting
May 22, 2025 21:00
Bicara Therapeutics to Present Updated Data from Ongoing Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
Apr 23, 2025 14:00
Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Sep 16, 2024 20:01
Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Sep 16, 2024 20:01